In a bid to reinvigorate sales of its cancer therapy Rytelo, Geron is reducing its headcount by a third and said it will use the savings to strengthen its commercial strategy and execution for the drug. The company currently has about 260 employees, so the layoffs will affect about 87 people, according to a Thursday news release.
All entries for: Hematology
November 25, 2025
Novartis
Layoffs
Basel, Switzerland
10,001-50,000 employees
Novartis will cut 550 full-time jobs at a facility in Switzerland by the end of 2027. The cuts come as the pharma company is ending production of tablets, capsules, and sterile medicine packaging at a plant in Stein, Switzerland.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 17, 2025
Bristol Myers Squibb
Layoffs
Lawrenceville, NJ
10,001-50,000 employees
Bristol Myers Squibb has announced another round of layoffs, affecting 110 employees at the Lawrence Township site.
Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 14, 2025
Actinium Pharmaceuticals, Inc
Neutral Outlook
New York, NY
1-50 employees
We currently believe that our targeted radiotherapies, which utilize biologic molecules, are less likely than small molecules to face pricing pressure and negotiation from the Inflation Reduction Act of 2022 (“IRA”), given that small molecules are at risk for pricing negotiations seven years after approval compared to eleven years for biologics with negotiated prices taking effect two years after selection.
Disease Area: Hematology, Oncology
Drug Type: Biologic
November 10, 2025
Akebia Therapeutics, Inc.
Neutral Outlook
Cambridge, MA
201-500 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).
Disease Area: Chronic Disease, Hematology, Multiple
Drug Type: Small Molecule
November 7, 2025
GERON CORP
Negative Outlook
Foster City, CA
51-200 employees
The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including the Medicare Drug Price Negotiation Program, which may ultimately have a negative effect on the pricing for RYTELO.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule
November 6, 2025
Disc Medicine, Inc
Neutral Outlook
Watertown, MA
51-200 employees
The Inflation Reduction Act of 2022, or the IRA, includes several provisions that may impact our business, depending on how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay until January 1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge.
Disease Area: Hematology
Drug Type: Small Molecule
November 5, 2025
Vor Biopharma Inc Cambridge
Neutral Outlook
Cambridge, MA
51-200 employees
The Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. We cannot predict the ultimate content, timing or effect of any such challenges or changes to the ACA or other federal and state reform efforts.
Disease Area: Hematology, Immune Diseases, Multiple
Drug Type: Biologic
November 5, 2025
Keros Therapeutics, Inc
Neutral Outlook
Lexington, Massachusetts,
51-200 employees
The Inflation Reduction Act of 2022, or the IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is unclear how any additional healthcare reform measures of the second Trump administration will impact the ACA and our business.
Disease Area: Hematology, Rare Diseases
Drug Type: Biologic
November 4, 2025
Rigel Pharmaceuticals Inc
Neutral Outlook
South San Francisco, CA
51-200 employees
While it remains to be seen how the drug pricing provisions imposed by the IRA will affect the broader pharmaceutical industry, several pharmaceutical manufacturers and other industry stakeholders have challenged the law, including through lawsuits brought against the DHHS, the Secretary of the DHHS, CMS, and the CMS Administrator challenging the constitutionality and administrative implementation of the IRA’s drug price negotiation provisions.
Disease Area: Hematology, Oncology
Drug Type: Small Molecule